Ginkgo Bioworks (DNA) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed REGENXBIO (RGNX) over the past year, losing 8.7% versus a loss of 39.3%. Over five years, RGNX leads with a -76.9% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $473.4 million), about 1.0 times the size, while REGENXBIO is growing revenue faster (+104.5% vs -25.1%).
REGENXBIO converts more of its revenue into profit, with a net margin of -113.8% versus -183.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | RGNX |
|---|---|---|
| Share price | $7.46 | $7.16 |
| Market cap | $483.54M | $473.44M |
| 1-day change | -9.02% | -0.28% |
| YTD return | -10.23% | -50.28% |
| 1-year return | -8.69% | -39.32% |
| 5-year return | -98.45% | -76.87% |
| EPS (TTM) | $-4.24 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | $170.44M |
| Revenue growth (YoY) | -25.06% | +104.54% |
| Net income (latest FY) | $-312.76M | $-193.88M |
| Operating margin | -185.29% | -94.58% |
| Net margin | -183.81% | -113.75% |
| 52-week high | $18.22 | $16.19 |
| 52-week low | $5.37 | $5.46 |
| Distance from 52-week high | -59.06% | -55.78% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | +7.24% | +198.88% |
| Average volume | 2.53M | 1.39M |
| Shares outstanding | 53.94M | 66.12M |
| Employees | 485 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNA has outperformed RGNX by 30.6 percentage points over the past year.
- REGENXBIO is more profitable, keeping -113.8 cents of every revenue dollar as net income versus -183.8 cents for Ginkgo Bioworks.
- REGENXBIO grew revenue faster in its latest fiscal year (+104.54% vs -25.06%).
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
DNA vs RGNX FAQ
Which is bigger, Ginkgo Bioworks or REGENXBIO?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $473.44M for REGENXBIO (RGNX).
Which stock has performed better over the past year, DNA or RGNX?
DNA returned -8.69% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.